Literature DB >> 1254947

Resistance to murine leukemia in mice rejecting syngeneic somatic hybrid cells.

W Liang, E P Cohen.   

Abstract

(A/J X C3H/HeJ) F1 mice reject somatic cell hybrids of ASL-1 cells (A origin) and LM(TK)- cells (C3H origin), but die from leukemia within 10 days after the inoculation of approximately 10(6) viable ASL-1 cells. Mice rejecting hybrid cells survive for prolonged periods after challenge with otherwise lethal numbers of ASL-1 cells. The hybrid cells, rejected by syngeneic F1 recipients, retained their oncogenic potential as determined by the appearance and progressive growth of tumors in immunologically deficient nu/nu mice injected with the cells. Similar results were obtained using hybrids of a radiation-induced cell line (RADA-1), maintained by serial transfer in strain A mice and LM(TK)- cells. Syngeneic mice injected with RADA-1 X LM(TK)- cells failed to form tumors. Mice rejecting RADA-1 X LM(TK)- hybrid cells survived for prolonged periods after challenge with otherwise lethal numbers of RADA-1 cells.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1254947

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Cytotoxic activity toward mouse melanoma following immunization of mice with transfected cells expressing a human melanoma-associated antigen.

Authors:  J Nowak; E P Cohen; L H Graf
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Surface antigens of immunoprotective leukaemia x fibroblast hybrid cells which have lost malignant properties in histocompatible mice differ from the malignant parental cells.

Authors:  R Slomski; D R Wang; E P Cohen
Journal:  Immunology       Date:  1984-06       Impact factor: 7.397

3.  Immunity to melanoma in mice immunized with transfected allogeneic mouse fibroblasts expressing melanoma-associated antigens.

Authors:  Y S Kim; R Slomski; E P Cohen
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.